National safety data of post-marketing use of omalizumab in severe persistent asthma in Turkey

Simple item page
dc.contributor.authorDursun, Adile Berna
dc.contributor.authorBavbek, Sevim
dc.contributor.authorMısırlıgil, Zeynep
dc.contributor.authorErdener, F.
dc.contributor.authorBüyüköztürk, Suna
dc.contributor.authorAydın, Ömür
dc.contributor.authorGemicioğlu, Bilun
dc.contributor.authorBayrak, P.
dc.contributor.authorErkekol, Ferda Öner
dc.contributor.authorYıldırım, Zeki
dc.contributor.authorÇilli, Aykut
dc.contributor.authorBoz, Bingol A.
dc.contributor.authorAlpaydın, Özgen A.
dc.contributor.authorKarakoç, Bingol G.
dc.contributor.authorGörgüner, Metin
dc.contributor.authorKarakaya, Gül
dc.contributor.authorIşık, Rüveyda
dc.contributor.authorBakırtaş, Arzu
dc.contributor.buuauthorSapan, Nihat
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Çocuk Sağlığı ve Hastalıkları Anabilim Dalı.tr_TR
dc.date.accessioned2022-03-17T12:32:00Z
dc.date.available2022-03-17T12:32:00Z
dc.date.issued2011-06
dc.descriptionBu çalışma, 11-15 Haziran 2011 tarihleri arasında İstanbul[Türkiye]’da düzenlenen 30th Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI)’da bildiri olarak sunulmuştur.tr_TR
dc.description.sponsorshipEuropean Acad Allergy & Clin Immunol (EAACI)en_US
dc.identifier.citationDursun, A. vd. (2011). "National safety data of post-marketing use of omalizumab in severe persistent asthma in Turkey". Allergy, 66(Supplement 94), Special Issue SI, 675-676.en_US
dc.identifier.endpage676tr_TR
dc.identifier.issn0105-4538
dc.identifier.issn1398-9995
dc.identifier.issueSupplement 94en_US
dc.identifier.startpage675tr_TR
dc.identifier.urihttp://hdl.handle.net/11452/25149
dc.identifier.volume66tr_TR
dc.identifier.wos000329462204080
dc.indexed.wosSCIEen_US
dc.indexed.wosCPCISen_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.collaborationSanayitr_TR
dc.relation.collaborationYurt içitr_TR
dc.relation.journalAllergyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAllergyen_US
dc.subjectImmunologyen_US
dc.subject.wosAllergyen_US
dc.subject.wosImmunologyen_US
dc.titleNational safety data of post-marketing use of omalizumab in severe persistent asthma in Turkeyen_US
dc.typeMeeting Abstract
dc.wos.quartileQ1en_US

Files

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Web of Science